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Abstract: In the absence of an effective vaccine and lack of a complete cure, gene therapy 
approaches to control HIV infection offer feasible alternatives. Due to the chronic nature of 
infection, a wide window of opportunity exists to gene modify the HIV susceptible cells 
that continuously arise from the bone marrow source. To evaluate promising gene therapy 
approaches that employ various anti-HIV therapeutic molecules, an ideal animal model is 
necessary to generate important efficacy and preclinical data. In this regard, the humanized 
mouse models that harbor human hematopoietic cells susceptible to HIV infection provide 
a suitable in vivo system. This review summarizes the currently used humanized mouse 
models and different anti-HIV molecules utilized for conferring HIV resistance. 
Humanized mouse models are compared for their utility in this context and provide 
perspectives for new directions. 
Keywords: gene therapy for HIV/AIDS; humanized mice for HIV gene therapy; stem  
cell-based gene therapy; anti-HIV RNA-based therapies; new generation humanized mice 
 
1. Introduction 
The advent of combinatorial antiretroviral therapy proved to be highly effective in controlling HIV 
disease progression to full blown AIDS and thus in dramatically decreasing the mortality rates where 
treatment is available [1]. However, major current issues are systemic drug toxicity and generation of 
drug resistant viral mutants during prolonged therapy. In addition, viral latency remains an intractable 
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problem [2,3]. Therefore, alternative innovative approaches are continually being pursued to provide 
an effective cure. Among these are immune-augmentation protocols to reinvigorate the immune 
system [4] and gene therapy strategies to render HIV susceptible cells impervious to virus infection at 
the entry level and/or interfere with intracellular virus replication [5,6]. These approaches show 
considerable promise due to the inherent nature of HIV infection and disease progression. First, unlike 
acute viral diseases wherein pathogenesis is rapidly occurring in a span of few days, HIV is a chronic 
disease, thus providing a wide window of opportunity to interfere with the slow disease progression. 
Second, the viral susceptible cells are of hematopoietic origin, which are generated on a continued 
basis from the bone marrow source wherein the precursor cells reside. Thus, therapies can be 
effectively directed to the newly generated hematopoietic cells, or alternatively the precursor stem 
cells themselves can be genetically altered such that their progeny can be made virus resistant. 
For the success of HIV gene therapy strategies, a number of important criteria need to be met:  
(1) An effective gene therapeutic construct should be able to permanently disable a critically needed 
host factor for viral infection and/or potently inhibit virally-encoded messages and/or proteins.   
(2) Appropriate gene delivery vehicles with minimal toxicity such as gene transducing viral vectors 
are needed that have high efficiency of gene transduction into HIV target cells or their progenitors.  
(3) The anti-HIV genes should have long term efficacy and should not promote generation of viral 
escape mutants. (4) They should not display adverse effects on lineage specific differentiation and 
immunological function. (5) Finally, promising anti-HIV gene therapeutic constructs need to be 
evaluated in a suitable in vivo system to derive critical preclinical data necessary for subsequent 
human clinical trials. This review is mainly focused on currently available humanized mouse models 
and their utility in testing a variety of anti-HIV gene constructs. 
2. An Ideal in Vivo Animal Model for HIV Gene Therapy  
HIV is a human virus causing severe disease in its natural host. While chimpanzees can be infected 
with HIV, they rarely show severe disease. In comparative studies, non-human primate (NHP) 
macaque models employing related simian immunodeficiency virus (SIV) and chimeric viruses such as 
simian-human immunodeficiency viruses (SHIVs) have yielded important data [5]. However, their 
utility is somewhat limited to derive full-fledged relevant data on HIV. In this regard, humanized mice 
transplanted with HIV susceptible human cells currently are becoming indispensable for testing 
various anti-HIV constructs [7] (Figure 1). While a variety of humanized mice are currently available, 
an ideal model should satisfy the following criteria. (1) They should harbor HIV susceptible cells long 
term and permit chronic HIV infection and helper CD4 T cell loss. (2) Ideally they should 
continuously generate the full spectrum of HIV susceptible cells, namely CD4 T cells, macrophages 
and dendritic cells which are primary viral targets. (3) They should permit HIV viral latency as   
seen in a typical HIV patient. (4) Finally they should generate human immune responses such that 
immune-restoration by gene therapy strategies can be effectively evaluated. 
3. Immunodeficient Strains Used to Generate Humanized Mice 
Various humanized mouse models have been used to test gene therapy strategies since the concept 
of intracellular immunization for HIV was conceived [7,8]. A common denominator has been the 
utilization of immunodeficient mice which do not reject xenografts for human cell reconstitution. Viruses 2013, 5  3121 
 
Among the early immunocompromized mice is the SCID mouse which lacks T and B cells which 
permitted creation of hu-PBL-SCID and SCID-hu mouse models [9–12]. Later improvements led to 
generation of NOD-SCID mice with lower levels of NK cells and innate immunity, permitting 
improved levels of human cell engraftments [13]. A subsequent innovation was the targeted 
inactivation of the murine IL-2 receptor common gamma chain (IL2-Rcγ) gene, thus nullifying the 
actions of native mouse cytokines IL-2, IL-4, IL-7, IL-9, IL- 15 and IL-21 [13,14]. This trait, when 
bred into mice harboring SCID, NOD, RAG1 or RAG2 gene mutations yielded more severe 
immunocompromized mice (Rag2
−/− cγ
−/− , Rag1
−/− cγ
−/− (RG), NOD/shi-scid/cγ
−/− null (NOG) and 
NOD/SCID/cγ
−/− (NSG) mice) which were far superior for human cell engraftment [7,15,16]. 
Transplantation with human hematopoietic stem cells (HSC) into these mice leads to generation   
of all the necessary human immune cell subsets, namely T, B, NK cells, macrophages and dendritic 
cells [17,18]. Levels of different cell sets vary in different mouse models, for example NK cells are 
produced in suboptimal levels [19], but can be increased with IL-15 treatment. Both humoral and cell 
mediated immune responses are seen [20]. Newer refinements currently underway include introduction 
of human HLA Class I and II immune system and cytokine genes to generate more robust human 
immune responses [15,21]. 
Figure 1. Modeling HIV gene therapy in humanized mice and clinical application. 
 
4. Currently Used Humanized Mouse Models 
Different versions of humanized mice (Hu-Mice) currently exist, each with its own advantages and 
disadvantages [7]. A major distinguishing feature of new Hu-Mouse models with those of the earlier 
versions is their ability to support primary human immune responses. A general description describing 
various features and their utility for testing gene therapy approaches is detailed below and summarized 
in Table 1. Viruses 2013, 5  3122 
 
Table 1. Current Humanized Mouse Models and Preclinical Gene Therapy Studies. 
Model 
Method (Mouse 
Strain) 
Advantages Disadvantages 
Gene Therapy Approaches 
Studied 
Hu-
PBL 
i/p injection of 
human PBMC.  
(SCID, NOD-SCID, 
NSG, NOG) 
Easy to produce. 
Immediate use.  
Good T cell 
engraftment. 
Lacks multilineage 
hematopoiesis.  
Lacks primary 
immune response. 
Graft versus host 
disease. 
CCR5 shRNA [22,23] 
tat-rev shRNA [24] 
vif/pol shRNA [25] 
antisense env [24] 
fusion inhibitor [24] 
BNAb [26] 
TCR [27] 
TRIM5α [28] 
ZFN for CCR5 [29] 
ZFN for CXCR4 [30,31] 
LEDGF/p75 [32] 
Hu-
HSC 
Intrahepatic injection 
of CD34
+ HSC into 
neonates.  
Intravenous injection 
of CD34+ HSC into 
adults.  
(Rag2
−/− yc
−/−, NSG, 
NOG) 
Easy to produce. 
Multilineage 
hematopoiesis. 
Primary humoral and 
cellular immune 
responses.  
IgM production. 
Mucosal engraftment. 
Weak human HLA 
restriction.  
Weak IgG 
production. 
CCR5 shRNA [33,34] 
gag, pol shRNA [35] 
tat-rev shRNA [35,36] 
nef shRNA [37] 
LTR shRNA [38] 
antisense env [39] 
TAR decoy [34] 
fusion inhibitor [36] 
BNAb [40] 
TRIM5α [33,34] 
ZFN for CCR5 [41] 
SCID-
Hu 
Co-implantation of 
human fetal liver and 
thymic tissue under 
kidney capsule.  
(SCID or NOD-
SCID) 
Abundant T cell 
lymphopoiesis. 
Surgery needed, 
labor intensive.  
Requires human 
fetal tissue.  
No multilineage 
hematopoiesis.  
No primary immune 
response.  
Poor peripheral T 
cell engraftment. 
Integrase antibody [42] 
tat-rev shRNA [43] 
rev shRNA [44] 
TAR decoy [43,45] 
CCR5 ribozyme [43,45,46] 
tat-rev ribozyme rev aptamer 
[47] 
CCR5 intrabody [48] 
TRIM5α [28] 
Transgenic TCR [49] 
RevM10 [50] 
BLT 
Co-implantation of 
human fetal liver and 
thymic tissue under 
kidney capsule with 
additional i/v 
injection of 
autologous CD34+ 
HSC.  
(Rag2
−/− yc
−/−, NOD-
SCID, NSG) 
Multilineage 
hematopoiesis.  
Primary humoral and 
cellular immune 
responses.  
IgM production. 
Presence of human 
thymus.  
Human HLA T cell 
restriction.  
Mucosal engraftment. 
Surgery needed, 
labor intensive.  
Requires human 
fetal tissue. Weak  
IgG production. 
CCR5 shRNA [51,52] 
LTR shRNA [52] 
transgenic TCR [53] 
BNAb [54] Viruses 2013, 5  3123 
 
Hu-PBL mice: By far the easiest model to prepare, this model is created by engraftment of human 
mature PBMCs by i/p route into SCID, NSG or RG mouse strains [10]. Human immune cells   
persist for many weeks and HIV-1 can productively infect these mice. However, the injected cells 
eventually decline and no notable primary immune responses could be seen due to lack of de novo 
multilineage human hematopoiesis. Graft versus host disease is a problem, thus complicating the 
interpretation of results. 
SCID-hu mice: Surgical co-implantation of human fetal thymus and liver fragments under   
the SCID mouse kidney capsule generates mice harboring a functional human thymus (thy/liv 
organoid) [9]. There is robust thymopoiesis with generation of both CD4 and CD8 mature T cells [55]. 
HIV infection leads to severe depletion of both mature and immature CD4 T cells. A drawback with 
this model is human immune responses are lacking due to the absence of the full array of human 
immune cells. 
Hu-HSC mice: These are generated by transplantation with hematopoietic stem cells (HSC)   
into either adult or neonatal mice. IL-2Rcγ
−/− mice such as RG, NOG or NSG mice are commonly 
utilized [7,13]. Engraftment of HSC into conditioned newborn mice via routes such as intra-hepatic 
injection results in superior human cell engraftment with generation of a full complement of T cells, B 
cells, macrophages, NK cells and dendritic cells [17,18]. HIV infection leads to chronic viremia lasting 
more than a year with concomitant CD4 T cell loss [56]. Human antibody responses are seen [57]. 
While cell mediated immune responses are detected, they are not human HLA restricted [58]. Mucosal 
human cell engraftment permits HIV vaginal transmission, thus permitting viral challenges by the 
natural route of infection to assess viral resistance conferred by anti-HIV genes [54,59,60]. 
BLT mice: These are created by a modification and improvement of the earlier SCID-hu mouse 
model by additional engraftment with autologous HSC (bone marrow, liver and thymus) [61,62]. 
Superior human cell engraftment with multilineage generation of T cells, B cells, macrophages, NK 
cells and dendritic cells is seen. Presence of a functional autologous human thymus in this model 
permits appropriate T cell education and human HLA cell restriction. HIV infection leads to viremia 
and helper CD4 T cell loss. Good mucosal human cell engraftment is seen thus permitting mucosal 
viral challenges [63].  
5. Preclinical Gene Therapy Questions that Can be Effectively Assessed in Humanized Mice 
In vitro evaluation of various anti-HIV gene therapy constructs in lab adopted T cell lines and 
human PBMCs provides preliminary efficacy data. However, many important physiological questions 
cannot be answered by these. Therefore, it is essential that promising strategies be tested in vivo. 
Among these are, how long does the efficacy last and do escape viral mutants arise after prolonged 
use? What types of toxicities such as adverse cytokine production are associated with in vivo use? For 
stem cell-based strategies it needs to be evaluated whether a particular anti-HIV construct displays 
adverse effects on the stem cell lineage specific differentiation into the end stage hematopoietic cells 
such as T cells, B cells, macrophages and dendritic cells. Is there any gene silencing/deletion occurring 
during prolonged in vivo application? Do some specific gene transduced cells have preferential clonal 
expansions and possibly have oncogenic potential? With specific gene transducing vectors it also 
needs to be determined if there is a preference to integrate into selective chromosomal sites. Can 
different anti-viral constructs when introduced in combination work synergistically in providing   Viruses 2013, 5  3124 
 
anti-viral protection? Finally, are the gene transduced lineage specific differentiated cells functionally 
competent and work synergistically with other cell types in generating an effective immune response 
such that immune functions can be restored in the AIDS patient? Features that distinguish the newer 
generation hu-HSC and BLT humanized mouse models from those of previous hu-PBL and SCID-hu 
mouse models are de novo multilineage human hematopoiesis and the capacity for generating both 
adaptive and innate immune responses [15,20]. Therefore many of the above questions can be 
effectively evaluated in an experimental setting to derive important pre-clinical data. 
6. Anti-HIV Gene Therapy Constructs 
HIV is a highly evolved complex retrovirus with many unique features, especially a great tendency 
for genomic variation [64]. Antigenic variation in the infected host frustrates the immune system, thus 
posing a difficulty in controlling infection and in designing effective vaccines. Therefore, novel 
intracellular immunization strategies offer innovative avenues. Whereas mature CD4 T cells can be 
genetically modified to confer anti-viral resistance and/or potent effector functions, targeting   
these approaches to HSC will be long-lasting and therefore potentially conferring a permanent viral 
control [5,6]. For these strategies to be effective, vulnerable steps of the viral infection need to be 
targeted. To date, a great deal of data has accumulated on various stages of viral replication. Steps that 
are amenable to preventive/therapeutic targeting encompass both cellular and virally-encoded 
molecules. Among these are cellular receptors CD4, CCR5 and CXCR4, virally-encoded regulatory 
molecules such as tat and rev, and finally host factors that assist or restrict viral replication [5,8]. 
Varieties of anti-HIV constructs have been experimented both in vitro and in vivo. These fall into two 
broad categories, namely, nucleic acid based and protein based. A particular advantage with the 
nucleic acid based approaches versus protein-based is that they are not immunogenic and thus are 
more suitable for long-range application. The following is a brief description of the various constructs 
and how they have been successfully evaluated in humanized mice. For brevity, only representative 
examples are discussed with some historical perspective. 
7. RNAi  
The phenomenon of RNA interference (RNAi) is a native cellular process that can be exploited to 
silence any gene of choice [65]. It involves small RNAs that can perform post-transcriptional gene 
silencing (PTGS) as well as transcriptional gene silencing (TGS). TGS involves the prevention of 
transcription through epigenetic modification of DNA sequences. This approach is beginning to be 
harnessed to silence HIV [66]. PTGS involves either sequence specific cleavage of fully 
complementary target RNAs by siRNAs or translational inhibition and destruction of mRNAs that 
have imperfect complementary miRNAs. These pathways involve a complex set of intracellular 
reactions that employ a number of cellular proteins, with the final cleavage of the target RNA 
performed by an RNA induced silencing complex (RISC), which acts by endonuclease activity [67]. 
Since the discovery of RNAi, numerous reports described use of siRNAs to inhibit HIV in vitro, and 
some of these studies progressed to in vivo evaluation [5,8,68]. Both cellular and viral molecules 
essential for viral infection were targeted. For synthetic siRNA delivery into cells, most methods used 
a variety of transfection methods in addition to using novel molecules such as dendrimers [69,70]. For Viruses 2013, 5  3125 
 
infected cell-specific delivery, ligand-based approaches such as using antibodies or aptamers were 
employed [71–74]. The gene therapy approach calls for constitutive endogenous expression requiring 
incorporation of siRNA coding sequence into the target cell genomes. In this regard lentiviral vectors 
are the most commonly used for gene transduction [8]. 
One particular complication with the use of RNAi as a gene therapy for HIV involves the ability of 
HIV to generate escape mutations relatively easily. Even silent mutations with no consequences on the 
amino acid sequence (thus not conferring a fitness cost) could be sufficient to confer resistance to 
shRNA targeting viral transcripts [75]. Thus, for RNAi to be fully effective against HIV, it should be 
deployed as part of a combinatorial approach, either targeting multiple viral genes, or alternatively 
acting against cellular factors necessary for viral infection and/or replication. 
Among the prominent host cell targets evaluated in the RNAi context are the primary cell surface 
receptor CD4 and co-receptors CXCR4 and CCR5 [6,8]. Of these CCR5 received the most attention 
recently due to the now famous case of the “Berlin patient” who was cured of the HIV infection after 
allogenic bone marrow transplantation with CCR5 negative HSC [76,77]. Based on this example, 
many ongoing studies are directed towards silencing the CCR5 gene. 
In early studies evaluating CCR5 siRNAs using gene transduced human PBMCs in vivo in 
humanized mice, An et al. found that high expression levels achieved under the control of the U6 
promoter resulted in significant cytotoxicity [78]. However, this was avoided through the use of a 
weaker H1 promoter but resulting in the desirable levels of CCR5 down regulation. In later studies 
using a similar approach, CD34 HSCs were transduced and engrafted into BLT mice [51]. T cell 
development was normal and CCR5 knockdown was maintained during long term in vivo and these 
cells were resistant to HIV challenge ex vivo. For targeted delivery of CCR5 shRNA only into   
CCR5-expressing cells, a ZZ domain/monoclonal antibody conjugated Sindbis virus glycoprotein 
pseudotyped lentiviral vector was used [23]. In vitro results showed inhibition of HIV-1 replication, 
and in vivo results with NSG mice engrafted with these cells confirmed CCR5 expressing cells were 
targeted for transduction. Transduction of iPSCs with a lentiviral vector encoding CCR5 shRNA has 
also been tested, however, the in vivo efficacy of the transduced cells was not demonstrated [33]. A 
potential limitation of targeting only CCR5, however, is that such a strategy may promote selection of 
a CXCR4-tropic strain, with the possibility of a quicker progression to AIDS. 
In addition to host cell molecules, a number of virally-encoded RNAs were also targeted by 
siRNAs. Some examples are, tat,  rev,  nef and env. Many of these were successfully tested in 
humanized mice (See Table 1). SiRNAs against the viral tat-rev genes were found to be effective at 
inhibiting HIV in vivo and ex vivo [24,36,43]. shRNA for rev alone [44], nef alone [37], vif/pol [25], 
and the HIV LTR [38,52] have been shown to have efficacy as well in humanized mice, along with the 
full length antisense env gene [24,39]. More recently the safety of a multi-shRNA based gene therapy 
for HIV-1 targeting gag, pol and tat/rev, has been evaluated in humanized mice [35]. Phase I clinical 
trials using this construct are planned. 
8. Ribozymes 
Ribozymes are RNA molecules with catalytic activity which can cleave phosphodiester bonds 
present in target RNA sequences, and thus can be exploited for gene silencing. They can be custom 
designed to achieve site specific cleavage of desired target RNA molecules [78]. There was much Viruses 2013, 5  3126 
 
initial excitement in using ribozymes for clinical application, although later discovery of RNAi 
provided more potent molecules for similar applications. For HIV gene therapy, ribozymes were 
employed to target either host or virally-encoded RNAs, some of which were later evaluated in clinical 
trials [79,80]. Modest decreases in viral load and increases in frequencies of CD4 T cells were seen in 
treated individuals [80]. Similar to siRNAs, ribozymes are also non-immunogenic, thus avoiding the 
risk of immune rejection of gene transduced cells. 
In early in vivo studies of CCR5, specific ribozymes were incorporated into retroviral vectors and 
transduced into HSCs for gene therapy application [6]. Vector delivered ribozymes have played a key 
role in setting the stage for deriving preclinical data on transgene effects on hematopoietic lineage 
specific differentiation and expression in terminally differentiated cells such as T cells [42]. In these 
studies, the SCID-hu mouse model was used. Work of Bai et al. that tested a CCR5 ribozyme   
showed no adverse effects on thymocyte differentiation from retroviral gene transduced HSC [46]. 
Subsequent studies using a lentiviral vector that gave much higher transduction efficiencies showed 
similar results [45]. In vivo derived transgenic cells were found to resist ex vivo HIV challenge 
confirming the efficacy of the ribozyme in down regulating the CCR5 co-receptor in differentiated cells. 
Later studies in SCID-hu mice have also successfully tested the efficacy of anti-HIV tat-rev and env 
ribozymes [47]. In a combinatorial approach, CCR5 ribozymes were incorporated into a lentiviral vector 
that also harbored a TAR decoy and a tat-rev siRNA and tested in humanized mice [43] (see below). 
9. RNA Decoys and Aptamers 
RNA decoys consist of the protein binding sequences of parent native RNA molecules whereas 
RNA aptamers are derived by in vitro selection for high affinity binding [69]. These molecules 
sequester the cognate viral regulatory or essential proteins and neutralize their function. TAR decoys 
inhibit HIV by neutralizing viral tat protein and rev aptamers interfere with rev function. Both TAR 
decoys [45] and a rev aptamer [47] were evaluated in SCID-hu mice. Transgenic T cells derived  
in vivo were found to show anti-HIV resistance. Later studies used the TAR decoy in combination with 
anti-CCR5 ribozymes and tat-rev siRNAs [43], and a TAR decoy in combination with CCR5 shRNA 
and a chimeric human-rhesus macaque TRIM5α gene was shown in hu-HSC mice to have in vivo 
efficacy against HIV [34]. Many other aptamers to different viral or cellular targets were developed for 
use in gene therapy approaches and await in vivo testing in a gene therapy setting [81]. With regard to 
immune rejection, RNA decoys and aptamers are also considered to be safe due to lack of immunogenicity. 
10. Antibodies 
While antibody responses are typically generated in response to HIV-1 infection, they are found to 
be inadequate in control of viral replication due to the propensity of the virus for constant antigenic 
variation [82]. This feature of the virus has also been frustrating in the development of an effective 
vaccine. Therefore, novel gene therapy efforts have also been directed at boosting host humoral 
immunity by delivering anti-HIV antibody coding genes into human cells in vivo. A first report 
utilizing this strategy employed an SV40 vector encoding a variable antibody fragment against the 
viral integrase protein [42]. SCID-hu mice thy/liv grafts were injected with the vector leading to the 
production of antibody by the transduced thymocytes. HIV challenge in mice showed marked viral Viruses 2013, 5  3127 
 
resistance, supporting the value of this approach. Broadly neutralizing anti-HIV antibodies (bNAbs) 
are seen in a subset of HIV infected individuals [82]. These bNAbs are superior due to their high 
potency against a broad range of HIV strains, and therefore vaccines that can elicit these will have 
obvious advantages. However, induction of these in immunized individuals has not been accomplished 
with the current experimental vaccines. Therefore, supplementation of these via what is recently 
termed as vectored immunoprophylaxis shows considerable promise. 
Such an approach was first tested by using bNAb 2G12 in humanized mice [40]. An antibody 
encoding lentiviral vector was employed to transduce human HSC, which were then engrafted into 
NSG mice. Systemic 2G12 antibody production was seen, and there was marked reduction in viral 
loads upon HIV challenge compared to non-treated mice. A separate approach used a tumor cell 
“backpack” constitutively producing a dimeric 2G12 bNAb. Hu-Mice harboring this “backpack” 
showed reduced viral loads and preserved CD4 T cell levels [83]. Using a different vector, AAV 
coding for bNABs b12, 2G12, 4E10 and VRC01, humanized mice (NSG and RG mice backgrounds) 
were vaccinated intramuscularly, leading to systemic antibody production lasting as long as   
52 weeks [84]. Full protection from HIV challenge via i/v route was seen with the B12 and VRC01 
antibodies, whereas partial protection was seen with 2G12, 4E10, and 2F5 antibodies. Since HIV is 
transmitted primarily by sexual transmission by the mucosal routes and IgA is the predominant 
mucosal antibody, another study evaluated the efficacy of lentiviral vector delivered IgA [54]. In 
humanized NSG, BLT, and hu-HSC RG mice prepared by transplantation with antibody gene 
transduced HSC, the transgenes were expressed by B cells and plasma cells in both lymphoid organs 
and mucosal sites. While there was no protection from HIV infection following HIV-1 vaginal 
challenge, CD4 T cell depletion was drastically reduced in mucosal sites. 
Antibodies directed against host proteins involved in viral infection have also been tested in 
humanized mice in a different approach. CD34
+ HSCs were transduced with a lentiviral vector 
encoding a single chain CCR5 antibody (termed intrabody). During intracellular synthesis the 
intrabody prevents export of CCR5 protein to the cell surface. SCID-hu mice engrafted with the 
intrabody transduced HSC were found to be resistant to R5 tropic HIV infection [48]. 
11. Transgenic T cell Receptors 
Well chosen viral specific T cell receptors (TCRs) genetically introduced into primary T cells or 
HSCs have the potential to mediate potent effector T cell functions against infected cells expressing 
conserved viral antigens [8]. Therefore their exploitation for HIV gene therapy holds considerable 
promise. In vitro studies have documented the efficacy of such gene transduced CD8 T cells bearing 
transgenic TCRs in inhibiting HIV replication [84]. In vivo efficacy was evaluated by the use of a 
lentiviral vector containing a gag-SL9 (SLYNTVATL) specific TCR. Vector transduced human 
PBMC were injected into the spleens of SCID mice along with HIV infected PBMC [27]. Significantly 
lower viral titers were seen, suggesting that the engineered CTLs were able to exert some control over 
viral replication in vivo. In a stem cell based approach, human HSC transduced with a similar gag-SL9 
TCR and allowed to mature in SCID-hu mice thy/liv grafts [49]. Functional HIV specific CTLs were 
generated which recognized SL9 epitope in the context of proper HLA type. Later, this same group 
demonstrated in vivo suppression of HIV in NSG BLT mice prepared by injection of HSC transduced 
with gag-SL9 TCR [53]. Higher numbers of SL9-specific CD8 T cells in vivo correlated with lower Viruses 2013, 5  3128 
 
plasma viral loads. These data demonstrated the feasibility of cell mediated immune engineering 
against HIV. However, for a broad and long lasting protection it is necessary that multiple TCRs must 
be chosen carefully to target the most conserved HIV epitopes, since escape from CTL responses is 
common [85]. 
12. Transdominant Proteins 
Transdominant proteins exert their effect by interfering with the action of their counterpart native 
proteins involved in critical functions essential for viral replication. Some of these with anti-HIV 
properties have been evaluated in humanized mice to determine protection from HIV-1. An example is 
RevM10 that interferes with HIV rev protein action [50]. RevM10 encoding retroviral vector 
transduced CD34 HSC when engrafted into SCID-hu thymic grafts gave rise to normal T cells which 
upon ex vivo challenge showed HIV resistance. However, a disadvantage in a clinical setting is the 
immunogenicity of the protein leading to eventual elimination of gene transduced cells in vivo. Indeed 
in clinical trials this has not fared well, resulting in only a modest survival of CD4 T cells containing 
the RevM10 gene [86–88]. 
Another target of HIV-1 gene therapy tested in humanized mice is Lens Epithelium Derived Growth 
Factor (LEDGF) which is an essential cellular cofactor for viral integration [89]. Its inactivation by 
siRNAs or over expression of its C-terminal domain was shown to inhibit HIV-1 in vitro. This effect 
was also confirmed in vivo in humanized mice using gene transduced CD4 T cells [32]. Lower viral 
loads and protection from CD4 T cell decline were observed. 
13. Zinc finger, TALENS and CRISPR Nucleases 
Novel gene disruption methods employ gene targeted nucleases which encompass ZFN (zinc finger 
nucleases), TALENS (transcription activator-like effector nucleases), and CRISPR (clustered 
regulatory interspaced short palindromic repeats) systems [90–93]. ZFNs were among the nucleases 
initially exploited to silence the CCR5 gene to render HIV susceptible cells impervious to infection 
with the R5 tropic HIV, the predominant viral strain involved in natural viral transmission. Engineered 
ZFNs, which are an array of DNA-binding zinc fingers tethered covalently to a nonspecific FokI 
restriction nuclease, act by causing double strand DNA breaks at specific recognition sites leading to 
gene deletions and insertions thus permanently disabling a targeted gene [94]. An advantage with these 
is that their transient expression can lead to permanent gene disruption. In some of the first studies 
with CCR5 specific ZFNs, Perez et al. showed that human CD4 T cells that had been modified by 
ZFNs showed efficacy in humanized mice [95], with lower viral loads and preserved CD4 T cell 
levels. Later studies of Holt et al. also evaluated this approach in vivo in humanized mice using ZFN 
modified HSCs [41]. There was multilineage human hematopoiesis and generation of cells lacking the 
CCR5 receptor. HIV infection of these mice resulted in selection of CCR5 negative cells, lower viral 
loads and protection from CD4 T cell loss. More recently, an adenoviral vector encoding CCR5-ZFNs 
was used to modify human CD4 T cells, which were then engrafted into NSG mice to evaluate 
potential toxicity [29]. No detectable ZFN-specific toxicity or T-cell transformation was observed. 
ZFNs targeting the second coreceptor CXCR4 have also been evaluated in humanized mice [30,31]. 
When engrafted with zinc-finger modified CD4 T cells and challenged with X4 tropic virus, these Viruses 2013, 5  3129 
 
mice were shown to be resistant to in vivo challenge. However, disabling CXCR4 in HSCs has 
disadvantages since this receptor is indispensable for normal homing patterns and hematopoietic 
homeostasis. Potential downsides to the nuclease-based gene disruption approaches include the 
relatively modest bi-allelic gene modification and off target effects [96], resulting in unwanted 
disruption of important regulatory genes, possibly leading to malignancy. While no short term 
toxicities have been observed so far in ongoing clinical trials [29], long term follow up for several 
years is required to assess potential negative effects. 
TALENs, like ZFNs, bind to specific DNA sequences via transcription activator-like (TAL) 
proteins originally isolated from plant-pathogenic bacteria of the Xanthomonas species [97]. They 
create double stranded breaks through the action of covalently bound FokI nuclease domain [94]. They 
have an advantage of higher sequence specificity than ZFNs and relatively simple retargeting, with the 
disadvantage of a larger size and subsequent greater difficulty in delivery to target cells. 
Originally identified as elements of an adaptive immune system found in bacteria and archea, 
CRISPR, in constrast to ZFN and TALENs, relies on the use of guide RNA (gRNA) to deliver 
CRISPR-associated (Cas) nucleases [98]. When the gRNA bound to a codon-optimized Cas9 protein 
binds to a complementary sequence on DNA, it creates double strand DNA breaks at the unique target 
sequences. This has the advantages of even greater sequence specificity and is relatively easy to retarget 
to new sequences [99]. Potential off-target effects remain to be evaluated in future in depth studies. 
There has been considerable excitement in the use of TALENs or CRISPR to target the latent viral 
reservoir through disruption of the proviral genome. One in vitro study involving the CRISPR/Cas9 
system demonstrated inhibition of an HIV LTR [100]. In vivo studies on the use of TALENs and 
CRISPR for HIV prevention and therapies are the next step to establish their future clinical application. 
14. Host Restriction Factors 
As a host defense, mammalian cells encode many dominant acting proteins that help suppress viral 
replication. These are termed host restriction factors [101]. With regard to HIV restriction, a number of 
such factors were identified. Prominent ones are TRIM5α, TRIMcyp, APOBEC 3F and G, SAMHD1 
and tetherin, which can potentially be harnessed for HIV gene therapy. Many in vitro studies evaluated 
their anti-HIV effects. With regard to in vivo testing in humanized mice, early reports used a chimeric 
human-rhesus TRIM5α [28], which was humanized to reduce potential immunogenicity while 
retaining the critical rhesus macaque motif responsible for HIV restriction. HSCs were transduced with 
a lentiviral vector containing this construct and introduced into SCID-hu grafts. The transgenic T cells 
matured in these mice were found to be HIV resistant. In a different study, a human version of the 
monkey AoTRIM5Cyp (hT5Cyp) was transduced into human CD4 T cells and evaluated in hu-PBL 
mice [102]. Viral challenge experiments demonstrated decreased HIV viral loads and protection from 
CD4 T cell decline. Chimeric versions of TRIM5α in combination with other anti-HIV genes were also 
tested in vivo in humanized mice with encouraging results [34] (see below). A note of caution with the 
use of modified restriction factors for long-range gene therapy, however, is the potential for generating 
unwanted human immune responses, thus mitigating the expansion and survival of these transgenic 
cells in vivo.  
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15. Fusion Inhibitors  
Clinically licensed peptide drugs such as enfuvirtide (T20) inhibit HIV entry by interfering with 
viral fusion with the cell membranes [103]. A fusion inhibitor C46 (derived from a 46 amino acid 
sequence of gp41) with a similar structure to T20 can be stably expressed as a membrane anchored 
peptide (maC46) in retro or lentiviral vector transduced cells thus enabling its use as a gene therapeutic 
construct. C46 was tested in hu-PBL mice by introducing gene transduced CD4 T cells which showed 
efficacy [24]. When compared with two other anti-HIV constructs, namely a tat-rev siRNA and an 
antisense RNA VRX494, it was found to confer higher selective survival advantage in vivo. These 
studies did not address potential immunogenicity of the peptide, however, which remains a concern for 
long term efficacy. 
16. Combinatorial Approaches 
Due to the ability of HIV to rapidly mutate and escape under selective pressure, the early   
mono-antiretroviral therapies were not fully effective during long-term use. Use of combinatorial ART 
(HAART) has overcome this problem to a large extent [1]. Similarly, use of a single anti-HIV gene 
therapeutic construct will invariably lead to generation of viral escape mutants thus requiring the 
design and utilization of an ideal combinatorial construct for effective viral control. Based on this 
premise, many studies investigated this approach using viral vectors that harbor multiple genes [5]. 
Ideally, a combination of anti-HIV constructs with different mechanisms of action targeted to different 
stages of viral life cycle is desirable. A number of different constructs that include ribozymes and 
siRNAs targeted to both cellular and viral RNA targets, fusion proteins and restriction factors in 
different combinations were evaluated, some of which have been tested in vivo in humanized mice. 
Among these, one study employed a triple anti-HIV gene encoding lentiviral vector harboring a TAR 
decoy, CCR5 ribozyme and a tat-rev siRNA [43]. HSCs transduced with this combinatorial vector 
gave rise to HIV resistant cells when engrafted into SCID-hu mouse thy/liv grafts, providing data for a 
subsequent human clinical trial. In another study, a triple combination of CCR5 siRNA, chimeric 
human/rhesus TRIM5a and TAR decoy was evaluated in hu-HSC mice [34]. These studies, in addition 
to showing anti-viral efficacy, also demonstrated no apparent toxicity with the combination of genes, 
although neither study directly compared the effectiveness of combination therapy versus their 
respective single therapies. An in vitro study, however, showed that while HIV-1 can escape from a 
single shRNA, this was not the case when four anti-HIV shRNAs were expressed in the same cell [104]. 
As can be seen, humanized mice have been instrumental for deriving important pre-clinical data. 
17. Clinical Studies and Future Directions  
While numerous in vitro and in vivo studies laid the groundwork by identifying a large variety of 
anti-HIV constructs for testing gene therapy strategies, only a few of these reached clinical trials [105] 
(summarized in Table 2). Most were phase I studies aimed at safety and feasibility. Previous stem  
cell based trials involved retroviral vectors harboring RevM10 transdominant protein [88],   
RRE decoy [106,107] or anti-HIV ribozymes [80,108–110]. No adverse effects were seen in patients 
receiving the treatment, thus showing safety. While there were detectable levels of transgene Viruses 2013, 5  3131 
 
expressing cells, the gene marking levels were too low, however, to provide any durable clinical 
benefit. In a recent combinatorial approach using HSC, the triple lentiviral vector described   
above containing a CCR5 ribozyme, TAR decoy and a tat-rev siRNA was tested in AIDS lymphoma 
patients [79]. Again, levels of gene marking were low and there was no clinical benefit. Many phase 
I/II clinical trials also evaluated gene transduced T cells, again showing less than ideal levels of   
gene marking and persistence of gene modified cells [105]. Therefore, it is clear that a number of 
important hurdles need to be overcome to bring HIV gene therapy to a clinical reality. Among the 
main ones are “making space” for gene transduced HSC by myeloablation methods to allow durable 
engraftment, protocols to enable selection of gene modified cells, and high level gene transduction of 
the true and long lasting subpopulation of HSCs. In this regard, humanized mice can be exploited to 
evaluate new innovative experimental strategies to realize the full potential of gene therapy approaches 
in a clinical setting.  
Table 2. HIV Gene Therapy Clinical Trials.  
Gene therapy construct 
(viral or cellular target) 
Proprietary 
name 
Gene modified 
cells 
Delivery 
method 
Phase, status  Reference(s) 
Antisense (env mRNA)  VRX496 
Autologous CD4
+ 
T cells 
Lentiviral 
vector 
I-II, Ongoing 
[111–113] 
*NCT00622232
*NCT00295477
*NCT00131560 
ZFN (CCR5 gene)  SB 728T 
Autologous CD4
+ 
T cells 
Adenoviral 
vector 
I-II, Ongoing 
[114] 
*NCT01543152
*NCT01252641
*NCT01044654
*NCT00842634 
shRNA (CCR5 mRNA) 
Fusion inhibitor C46 (env 
protein) 
Cal-1 
Autologous 
CD34+ HSCs and 
CD4+ T cells 
Lentiviral 
vector 
I-II, Ongoing 
[115] 
*NCT01734850 
Fusion inhibitor C46 (env 
protein) 
M87o 
Autologous of 
Allogeneic 
CD34
+ HSCs 
Retroviral 
vector 
I-II, Ongoing 
[116] 
*NCT00858793 
Endoribonuclease (ACA 
sequences) 
MazF-T 
Autologous CD4
+ 
T cells 
Retroviral 
vector 
I, Ongoing  *NCT01787994 
Transgenic TCR (gag 
epitope) 
 
Autologous CD8
+ 
T cells 
Lentiviral 
vector 
I, Ongoing  *NCT0091224 
Chimeric antigen receptor 
(gp120 protein) 
 
Autologous CD4
+ 
and CD8
+ T cells 
Retroviral 
vector 
I-II, 
Completed 
[117–120] 
*NCT00001409
*NCT01013415 
Antisense (TAR, tat/rev 
mRNA) 
HGTV43 
Autologous 
CD34
+ HSCs 
Retroviral 
vector 
I-II, Ongoing  [121] 
Ribozyme (tat/vpr mRNA)  OZ1 
Autologous 
CD34
+ HSCs 
Retroviral 
vector 
II, Ongoing 
[80,122] 
*NCT01177059
*NCT00074997 
Ribozyme (tat/vpr mRNA)  Rz2 
Syngeneic CD4
+ 
T cells 
Retroviral 
vector 
I, Completed  [108,123–125] Viruses 2013, 5  3132 
 
Table 2. Cont. 
Gene therapy construct 
(viral or cellular target) 
Proprietary 
name 
Gene modified 
cells 
Delivery 
method 
Phase, status  Reference(s) 
Ribozyme (tat/rev mRNA)   
Autologous 
CD34
+ HSCs 
Retroviral 
vector 
II, Completed  *NCT00002221 
shRNA (tat/rev mRNA) 
TAR decoy (tat protein) 
Ribozyme (CCR5 mRNA) 
 
Autologous 
CD34
+ HSCs 
Lentiviral 
vector 
Pilot, 
Ongoing 
[79] 
*NCT01153464
*NCT00569985
Ribozyme (U5/pol mRNA)  MY-2 
Autologous CD4
+ 
T cells 
Retroviral 
vector 
I, Completed  [110] 
RRE decoy (rev protein)   
Autologous 
CD34
+ HSCs 
Retroviral 
vector 
Pilot, 
Completed 
[107] 
Transdominant rev  
(rev protein) 
 
Autologous 
CD34+ HSCs 
Retroviral 
vector 
I, Completed  [126,127] 
Transdominant rev 
 (rev protein) 
 
Autologous CD4
+ 
T cells 
Gold 
particles 
I, Completed  [128] 
Transdominant rev  
(rev protein) 
 
Autologous CD4
+ 
T cells 
Retroviral 
vector 
I, Completed  [88] 
Transdominant rev  
(rev protein) 
Antisense (pol mRNA) 
 
Autologous 
CD34+ HSCs 
Retroviral 
vector 
I/II, 
Completed 
*NCT00003942
* clinicaltrials.gov reference number 
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